Margaret A.WinkerMD, Deputy EditorIndividualAuthorPhil B.FontanarosaMD, Interim Co-EditorIndividualAuthor
Copyright 1999 American Medical Association.
All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.1999
To the Editor: Although
AFCAPS/TexCAPS1 resulted in a 37% decrease in heart
attacks and other serious manifestations of heart disease, there were
80 deaths among participants treated with lovastatin and 77 deaths
among participants treated with placebo. These results are no different
than those found in either the Lipid Research Clinics Coronary Primary
Prevention Trial (LRC-CPPT)2 or the Helsinki Heart Study
(HHS),3 earlier primary prevention studies that also
demonstrated a statistically significant decrease in a variety of
cardiac end points, but no decrease in total mortality.
Siegel D, Swislocki ALM. Coronary Events With Lipid-Lowering Therapy: The AFCAPS/TexCAPS Trial. JAMA. 1999;281(5):414-419. doi:10-1001/pubs.JAMA-ISSN-0098-7484-281-5-jbk0203